The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Nosratola D. Vaziri

Division of Nephrology and Hypertension

University of California

Irvine

Irvine

USA

[email]@uci.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Division of Nephrology and Hypertension, University of California, Irvine, Irvine, USA. 2001 - 2012
  • Correspondence and offprint requests to: Nosratola D. Vaziri; E-mail:. 2011 - 2012

References

  1. Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression. Vaziri, N.D., Yuan, J., Ni, Z., Nicholas, S.B., Norris, K.C. Clin. Exp. Nephrol. (2012) [Pubmed]
  2. Downregulation of the renal and hepatic hydrogen sulfide (H2S)-producing enzymes and capacity in chronic kidney disease. Aminzadeh, M.A., Vaziri, N.D. Nephrol. Dial. Transplant. (2012) [Pubmed]
  3. Effect of uremia on structure and function of immune system. Vaziri, N.D., Pahl, M.V., Crum, A., Norris, K. J. Ren. Nutr (2012) [Pubmed]
  4. Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease. Vaziri, N.D., Navab, K., Gollapudi, P., Moradi, H., Pahl, M.V., Barton, C.H., Fogelman, A.M., Navab, M. J. Natl. Med. Assoc (2011) [Pubmed]
  5. Lipid disorders and their relevance to outcomes in chronic kidney disease. Vaziri, N.D., Norris, K. Blood Purif. (2011) [Pubmed]
  6. Nephrotic syndrome causes upregulation of HDL endocytic receptor and PDZK-1-dependent downregulation of HDL docking receptor. Vaziri, N.D., Gollapudi, P., Han, S., Farahmand, G., Yuan, J., Rahimi, A., Moradi, H. Nephrol. Dial. Transplant. (2011) [Pubmed]
  7. Amelioration of nephropathy with apoA-1 mimetic peptide in apoE-deficient mice. Vaziri, N.D., Kim, H.J., Moradi, H., Farmand, F., Navab, K., Navab, M., Hama, S., Fogelman, A.M., Quiroz, Y., Rodriguez-Iturbe, B. Nephrol. Dial. Transplant. (2010) [Pubmed]
  8. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease. Vaziri, N.D. J. Ren. Nutr (2010) [Pubmed]
  9. Role of oxidative stress in the pathogenesis of erythropoietin-induced hypertension. Vaziri, N.D. Am. J. Hypertens. (2010) [Pubmed]
  10. In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Vaziri, N.D., Moradi, H., Pahl, M.V., Fogelman, A.M., Navab, M. Kidney Int. (2009) [Pubmed]
  11. Causes of dysregulation of lipid metabolism in chronic renal failure. Vaziri, N.D. Semin. Dial (2009) [Pubmed]
  12. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Vaziri, N.D., Zhou, X.J. Nephrol. Dial. Transplant. (2009) [Pubmed]
  13. Mechanisms of lead-induced hypertension and cardiovascular disease. Vaziri, N.D. Am. J. Physiol. Heart Circ. Physiol. (2008) [Pubmed]
  14. Anemia and anemia correction: surrogate markers or causes of morbidity in chronic kidney disease?. Vaziri, N.D. Nature Clinical Practice. Nephrology (2008) [Pubmed]
  15. Cardiovascular effects of lead exposure. Vaziri, N.D., Gonick, H.C. Indian J. Med. Res. (2008) [Pubmed]
  16. Causal link between oxidative stress, inflammation, and hypertension. Vaziri, N.D. Iran. J. Kidney. Dis (2008) [Pubmed]
  17. Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction. Vaziri, N.D., Bai, Y., Ni, Z., Quiroz, Y., Pandian, R., Rodriguez-Iturbe, B. J. Pharmacol. Exp. Ther. (2007) [Pubmed]
  18. Potential risks of nitric oxide inhibition in spinal cord injury. Vaziri, N.D. J. Spinal. Cord. Med (2007) [Pubmed]
  19. Interplay of reactive oxygen species and nitric oxide in the pathogenesis of experimental lead-induced hypertension. Vaziri, N.D., Khan, M. Clin. Exp. Pharmacol. Physiol. (2007) [Pubmed]
  20. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Vaziri, N.D. Am. J. Physiol. Renal Physiol. (2006) [Pubmed]
  21. Mechanisms of dyslipidemia of chronic renal failure. Vaziri, N.D., Moradi, H. Hemodial. Int (2006) [Pubmed]
  22. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Vaziri, N.D., Rodríguez-Iturbe, B. Nature Clinical Practice. Nephrology (2006) [Pubmed]
  23. Bradykinin down-regulates, whereas arginine analogs up-regulates, endothelial nitric-oxide synthase expression in coronary endothelial cells. Vaziri, N.D., Ding, Y., Ni, Z., Barton, C.H. J. Pharmacol. Exp. Ther. (2005) [Pubmed]
  24. Expression of NOX-I, gp91phox, p47phox and P67phox in the aorta segments above and below coarctation. Vaziri, N.D., Ni, Z. Biochim. Biophys. Acta (2005) [Pubmed]
  25. Role of AT-1 receptor in regulation of vascular MCP-1, IL-6, PAI-1, MAP kinase, and matrix expressions in obesity. Vaziri, N.D., Xu, Z.G., Shahkarami, A., Huang, K.T., Rodríguez-Iturbe, B., Natarajan, R. Kidney Int. (2005) [Pubmed]
  26. NAD(P)H oxidase, superoxide dismutase, catalase, glutathione peroxidase and nitric oxide synthase expression in subacute spinal cord injury. Vaziri, N.D., Lee, Y.S., Lin, C.Y., Lin, V.W., Sindhu, R.K. Brain Res. (2004) [Pubmed]
  27. Downregulation of hepatic acyl-CoA:diglycerol acyltransferase in chronic renal failure. Vaziri, N.D., Kim, C.H., Dang, B., Zhan, C.D., Liang, K. Am. J. Physiol. Renal Physiol. (2004) [Pubmed]
  28. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Vaziri, N.D. Curr. Opin. Nephrol. Hypertens. (2004) [Pubmed]
  29. Up-regulation of hepatic Acyl CoA: Diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome. Vaziri, N.D., Kim, C.H., Phan, D., Kim, S., Liang, K. Kidney Int. (2004) [Pubmed]
  30. Lead-induced hypertension: role of oxidative stress. Vaziri, N.D., Sica, D.A. Curr. Hypertens. Rep. (2004) [Pubmed]
  31. Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome. Vaziri, N.D., Liang, K.H. Circulation (2004) [Pubmed]
  32. ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure. Vaziri, N.D., Liang, K. Am. J. Physiol. Renal Physiol. (2004) [Pubmed]
  33. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Vaziri, N.D. Semin. Nephrol. (2004) [Pubmed]
  34. Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome. Vaziri, N.D., Liang, K. Am. J. Nephrol. (2004) [Pubmed]
  35. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Vaziri, N.D., Dicus, M., Ho, N.D., Boroujerdi-Rad, L., Sindhu, R.K. Kidney Int. (2003) [Pubmed]
  36. Superoxide dismutase, catalase, glutathione peroxidase and NADPH oxidase in lead-induced hypertension. Vaziri, N.D., Lin, C.Y., Farmand, F., Sindhu, R.K. Kidney Int. (2003) [Pubmed]
  37. Nitric oxide in microgravity-induced orthostatic intolerance: relevance to spinal cord injury. Vaziri, N.D. J. Spinal. Cord. Med (2003) [Pubmed]
  38. Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. Vaziri, N.D., Ni, Z., Oveisi, F., Liang, K., Pandian, R. Hypertension (2002) [Pubmed]
  39. Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome. Vaziri, N.D., Liang, K. Kidney Int. (2002) [Pubmed]
  40. Pathogenesis of lead-induced hypertension: role of oxidative stress. Vaziri, N.D. J. Hypertens. Suppl (2002) [Pubmed]
  41. Effects of aging and AT-1 receptor blockade on NO synthase expression and renal function in SHR. Vaziri, N.D., Wang, X.Q., Ni, Z.N., Kivlighn, S., Shahinfar, S. Biochim. Biophys. Acta (2002) [Pubmed]
  42. Effect of lead on nitric oxide synthase expression in coronary endothelial cells: role of superoxide. Vaziri, N.D., Ding, Y. Hypertension (2001) [Pubmed]
  43. The effect of pregnancy on renal clearance of boron in rats given boric acid orally. Vaziri, N.D., Oveisi, F., Culver, B.D., Pahl, M.V., Andersen, M.E., Strong, P.L., Murray, F.J. Toxicol. Sci. (2001) [Pubmed]
  44. Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure. Vaziri, N.D., Liang, K., Parks, J.S. Kidney Int. (2001) [Pubmed]
  45. Erythropoietin and transferrin metabolism in nephrotic syndrome. Vaziri, N.D. Am. J. Kidney Dis. (2001) [Pubmed]
  46. Compensatory up-regulation of nitric-oxide synthase isoforms in lead-induced hypertension; reversal by a superoxide dismutase-mimetic drug. Vaziri, N.D., Ding, Y., Ni, Z. J. Pharmacol. Exp. Ther. (2001) [Pubmed]
  47. Cardiovascular effects of erythropoietin and anemia correction. Vaziri, N.D. Curr. Opin. Nephrol. Hypertens. (2001) [Pubmed]
  48. Effect of chronic renal failure on nitric oxide metabolism. Vaziri, N.D. Am. J. Kidney Dis. (2001) [Pubmed]
 
WikiGenes - Universities